Pérez Cruz Elizabeth, Reyes Marín Arturo, Asbun Bojalil Juan, Arteaga Morfin Jose Ignacio
Metabolism and Nutritional Support Unit. Hospital Juárez de México..
Medicinas Departament. Hospital Juárez de México..
Nutr Hosp. 2015 Oct 1;32(4):1676-82. doi: 10.3305/nh.2015.32.4.9507.
malnutrition is a common complication in patients with cancer and is associated with immunosuppression and alterations with inflammatory response.
the aim of our study was to evaluate the effect of enteral nutrition supplemented with two enteral formulas on inflammatory markers (CRP, IL-6 and FNTα) in cancer patients undergoing chemotherapy.
randomized control trial, conducted at the Hospital Juarez of Mexico in patients with cancer undergoing chemotherapy with IRN < 97.5 and SGA B/C. Patients were randomly allocated to two groups: group I (immunomodulatory), group II (high ω3). The intervention began on the first day of chemotherapy until day 10 after. We evaluated nutritional status and an inflammatory marker on days 0, +5, +10 QT. Statistical analysis was performed with T Student, x2 and analysis of variance for repeated measurements. P < 0.05 was considered statistically significant.
a total of 29 patients were analyzed, 27 (62.8%) females and 16 (37.2%) males. Mean age 43.91 + 11.3 years old. Malnutrition prevalence was 48.8% moderate and 51.2% severe. Prealbumin levels significantly increase in group II vs group I (p < 0.05). Both groups maintenance body weight, lean mass and fat mass. No decrease levels of CRP, IL-6 and FNTα.
enteral supplementation during chemotherapy inhibits nutritional deterioration and maintenance body weight and lean mass. No decreased levels of inflammatory markers.
营养不良是癌症患者常见的并发症,与免疫抑制及炎症反应改变有关。
本研究旨在评估补充两种肠内营养制剂的肠内营养对接受化疗的癌症患者炎症标志物(CRP、IL - 6和FNTα)的影响。
随机对照试验,在墨西哥华雷斯医院对接受化疗且IRN < 97.5及SGA B/C的癌症患者进行。患者被随机分为两组:第一组(免疫调节组),第二组(高ω3组)。干预从化疗第一天开始直至化疗后第10天。在第0天、第5天、第10天QT评估营养状况和炎症标志物。采用t检验、卡方检验及重复测量方差分析进行统计分析。P < 0.05被认为具有统计学意义。
共分析29例患者,女性27例(62.8%),男性16例(37.2%)。平均年龄43.91 ± 11.3岁。营养不良患病率为中度48.8%,重度51.2%。与第一组相比,第二组前白蛋白水平显著升高(p < 0.05)。两组体重、瘦体重和脂肪量均维持稳定。CRP、IL - 6和FNTα水平未降低。
化疗期间肠内营养补充可抑制营养状况恶化,维持体重和瘦体重。炎症标志物水平未降低。